Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MI-CISDIR FAPI-PET/MRI in DCIS
2023-509860-47-00Phase 2Authorised
- Sponsor
- Universität Münster
- Start
- Apr 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gadobutrol and 68Ga FAPI-46 in breast cancer and ductal carcinoma in situ (DCIS), sponsored by Universität Münster. Primary endpoints: Sensitivity based on blinded readers’ PET/MRI visual assessment score and Specificity based on blinded readers’ PET/MRI visual assessment score. Planned start Apr 2024; status: authorised.
02
Drugs
gadobutrol68Ga FAPI-46
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on 2023-509860-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509860-47-00.